|
English
|
正體中文
|
简体中文
|
总笔数 :2815035
|
|
造访人次 :
27387496
在线人数 :
678
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"ichikawa k"的相关文件
显示项目 1-5 / 5 (共1页)
1
每页显示[10|25|50]项目
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3
|
Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-07-03T03:34:26Z |
Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3
|
Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-03T03:34:22Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2018-09-10T09:39:54Z |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody
|
Chen, K.-F.;Chen, H.-L.;Shiau, C.-W.;Liu, C.-Y.;Chu, P.-Y.;Tai, W.-T.;Ichikawa, K.;Chen, P.-J.;Cheng, A.-L.; PEI-JER CHEN; Kuen-Feng Chen; ANN-LII CHENG |
显示项目 1-5 / 5 (共1页)
1
每页显示[10|25|50]项目
|
